After missing out on FDA voucher, bluebird quickly raises funds to ...
WEBDec 19, 2023 · Now, bluebird is hurrying to raise millions of dollars—through two separate avenues—to fund the launch of its new sickle cell disease gene therapy and others.
press releases - bluebird bio, Inc.
WEBMay 29, 2024 · SOMERVILLE, Mass. --(BUSINESS WIRE)--Sep. 13, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31, 2022 , and for each of the first three quarters of 2022 and 2023.
Heard on repeat: Where are all the bluebirds this year? - Star Tribune
WEBJun 24, 2021 · Unseasonably severe winter cold in February through parts of the Central Plains and a swath of Southern states is believed to have killed untold numbers of bluebirds, some of which starved or...
bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line
WEBOct 3, 2022 · bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.
Bluebird's $2.8 million gene therapy becomes most expensive …
WEBAug 18, 2022 · Aug 17 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved bluebird bio's (BLUE.O) gene therapy for patients with a rare disorder requiring regular blood transfusions, and the...
Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA ... - MSN
WEBBluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Here’s Why. Story by Josh Nathan-Kazis. • 9mo. T wo weeks ago, bluebird bio secured Food and Drug...
bluebird bio Announces FDA Approval of LYFGENIA™ …
WEBDec 8, 2023 · Patients treated with LYFGENIA in bluebird bio-sponsored clinical studies will be monitored for a total of 15 years through a long-term safety and efficacy follow-up study (LTF-307). Conference...
bluebird bio Reports First Quarter 2024 Results and Highlights ...
WEBMay 9, 2024 · SOMERVILLE, Mass.--(BUSINESS WIRE)--May 9, 2024-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress.
bluebird bio gains FDA approval of gene therapy lovo-cel for ... - MSN
WEBThe U.S. FDA Friday approved bluebird bio's (NASDAQ: BLUE) Lyfgenia (lovo-cel), a gene therapy for sickle cell disease. The treatment uses a lentiviral vector -- a type of gene delivery vehicle...
bluebird bio Reports First Quarter 2024 Results and Highlights ...
WEBSOMERVILLE, Mass., May 09, 2024 -- (BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported first quarter results and business highlights for the...